Kerrie Prettitore, a young mother of three, was diagnosed with colon cancer in February 2014 and subsequently had successful surgery to remove the tumor. However, a rare genetic disorder had her fighting for her life after a single chemotherapy treatment. Kerrie didn’t know she was born with DPD Deficiency, which dramatically increases risk factors for 5-FU based chemotherapy. Read more about Kerrie’s story »
What is DPD Deficiency
DPD Deficiency (Dihydropyrimidine dehydrogenase deficiency) is a genetic disorder in which the body lacks the DPD enzyme. Roughly 4-8% of the population has some form of DPD Deficiency, ranging from partial to complete lack of the enzyme in their system. DPD is needed to break down the chemotherapy drugs 5-FU (fluorouracil) and capecitabine. Up to 30% of cancer patients receiving 5-FU experience severe toxicity (grades 3 and 4), yet testing is NEVER done before chemotherapy treatment begins. Patients with full or partial DPD Deficiency are at serious risk of neuroencephalopathy (brain damage) and death. Learn more about DPD Deficiency »
Our mission is to raise awareness of DPD deficiency while striving to make patient testing for DPD Deficiency a requirement prior to 5-FU based chemotherapy treatments. Read More »
Show your support with StrongMom Clothing and Wristbands
All proceeds raised from this site are considered donations and will be passed on to organizations like Advocates for Universal DPD Testing (AUDT) who are making strides to make testing for DPD/DPYD deficiency required prior to the start of chemotherapy with 5-FU (Fluorouracil) or Capecitabine (Xeloda).